No one’s really sure: “It’s astonishing that there’s still no real consensus on how CBD works,” says McLaughlin. “One thing we do know is that it doesn’t work through the same receptors as THC, and, in fact, seems to have the opposite effect.” THC mainly binds to a certain type of receptor (known as CB1) in the brain. But with CBD, he says, “there seems to be a lot of complex targets”—which means CBD may affect multiple pathways throughout the body.
CBD oil is not legal everywhere. It is banned/restricted by countries such as UAE, Dubai, and Saudi Arabia. Although CBD oil is illegal in many of the US states too, some have legalized its use for medicinal purposes. While the number would be ever-changing, as of 2016 there are 17 states in the US which have legalized the use of low THC, high CBD products for medical reasons in limited situations. These states include Alabama, Georgia, Iowa, Kentucky, Florida, Mississippi, Louisiana, Missouri, North Carolina, Oklahoma, South Carolina, Wisconsin, Wyoming, Tennessee, Texas, Utah, and Virginia. It is advisable to consult your local health specialist before use.
Recently I asked myself this very question and the more I read the more contradictory statements I found and the more confused I became. With an extensive background in medical marijuana and high THC strains I felt I had a good grasp on which one was “better” before I started researching for this article and could make a good argument for why medical marijuana derived CBD is better than hemp derived CBD. More recently I have been introduced to CBD derived from hemp and after some preliminary research I was not so sure. Fortunately, I have connections from within the industry and so my mission began. I set out to talk to the largest names on both sides of the spectrum and get their opinions on this matter.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160